Dr Cosette M. Wheeler has received support through her institution from Roche Molecular Systems for HPV genotyping studies and to conduct HPV vaccine studies for Merck and Co. Ltd. and GlaxoSmithKline. The other named authors do not have a commercial or other association that might pose a conflict of interest.
Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology†
Version of Record online: 16 JUL 2009
Copyright © 2009 UICC
International Journal of Cancer
Volume 126, Issue 3, pages 684–691, 1 February 2010
How to Cite
Maucort-Boulch, D., Plummer, M., Castle, P. E., Demuth, F., Safaeian, M., Wheeler, C. M. and Schiffman, M. (2010), Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int. J. Cancer, 126: 684–691. doi: 10.1002/ijc.24752
- Issue online: 8 DEC 2009
- Version of Record online: 16 JUL 2009
- Accepted manuscript online: 16 JUL 2009 12:00AM EST
- Manuscript Accepted: 25 JUN 2009
- Manuscript Received: 30 MAR 2009
- National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services. Grant Numbers: CN-55153, CN-55154, CN-55155, CN-55156, CN-55157, CN-55158, CN-55159, CN-55105
- Digene Corporation, Cytyc Corporation, Denvu, TriPathImaging, Inc., and Roche Molecular Systems
- 1Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 20–5., , , , , , , , , .
- 2Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425–34., , , , , , .
- 3The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–65., , , , .
- 4IARC. Monographs on the Evaluation of carcinogenic risks to Humans Volume 90: Human Papillomaviruses. Lyon: International Agency for Research on Cancer, 2007.
- 5Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831–6., , , , , , , , .
- 6A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582–9., , , , .
- 7High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419–24., , , , , , , .
- 8Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100: 513–7., , , , , , , .
- 9Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123–37., , , , , .
- 10Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66: 10112–9., , , , , , , , , , , , et al.
- 11Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 1406–12., , .
- 12Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415–23., , , , , , .
- 13Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006; 66: 11070–6., , , , , , , , , , , , et al.
- 14Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13: 839–46., , , , , , , .
- 15International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 1481–95.
- 16International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data on 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609–21.
- 17International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119: 1108–24.
- 18for the IARC Multi-centric Cervical Cancer Study Group. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 431–9., , , , , , , , , ,
- 19Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005; 116: 110–5., , , , , , , , , , , , et al.
- 20Effect of plasma micronutrients on clearance of oncogenic human papillomavirus (HPV) infection (United States). Cancer Causes Control 2003; 14: 319–26., , , .
- 21Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res 2004; 64: 8788–93., , , , , , .
- 22Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005; 14: 1149–56., , , , , , , .
- 23The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76–84., , , , , , , , , , , , et al.
- 24Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008; 123: 1685–92., , , , , , , , , , , , et al.
- 25Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 65–70., , .
- 26Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008; 68: 8813–24., , , , , , , , , .
- 27A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8–15., , , , , , , , , , , .
- 28Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184: 1508–17., , , , , .
- 29Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 Suppl 3: S3-78-S3/89., , , , , .
- 30Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648–59., , , , , .
- 31ASCUS and LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383–92.
- 32Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol 2008; 111: 1279–84., , .
- 33Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357–61., , , , , , , , .
- 34Analysis using Regression and Multilevel/Hierarchical Models. Cambridge: Cambridge University Press, 2007., .
- 35R development core team. R: A Language for Environmental and Statistical Computing. Vienna: R Foundation, 2008.
- 36Improved estimates of floating absolute risk. Stat Med 2004; 23: 93–104..
- 37A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003; 12: 477–84., , , , , , , , , .
- 38Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–8., , , , .
- 39The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006; 66: 10630–6., , , , , , , , .
- 40for the Instituto Nacional de Cancerologia HPV study group. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077–87., , , , , , , ,
- 41Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005; 162: 668–75., , , , , , , , .
- 42the HPV Study Group. Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia. Sex Transm Infect 2003; 79: 474–8., , , , , , , , , , and
- 43HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 87–93., , , , , , , , , , .
- 44Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360: 228–9., , , , , , , , , .
- 45the HPV Study Group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486–94., , , , , , , , , and
- 46Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 2000; 124: 203–11., , , , .
- 47Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998; 91: 973–6., , , .